• Tempest Therapeutics adjourned its October 14, 2026, special stockholder meeting because a proposed charter amendment lacked sufficient votes for approval.
• The amendment would replace specified supermajority voting requirements and permit stockholder action by written consent; it remains unapproved.
• The meeting will reconvene November 12, 2026, to allow additional voting on the unchanged proposal.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempest Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-111026), on October 20, 2026, and is solely responsible for the information contained therein.